17.2 C
July 21, 2024
Poultry & Livestock Review Africa
Health and Nutrition

New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows

Boehringer Ingelheim, a global leader in animal health, announces that Clinical and Laboratory Standards Institute (CLSI)* approved revised interpretive criteria for the susceptibility testing of Ubrolexin®.

According to the Federation of Veterinarians of Europe, wherever possible, susceptibility testing should be done to determine which antimicrobial will be most successful in treating a particular condition. Being able to test the susceptibility of an antibiotic combination that is dedicated to mastitis allows vet practitioners to appropriately select their treatment and prevent antibiotic resistance.

Ubrolexin®, a combination of kanamycin and cefalexin, has been marketed for the intramammary treatment of clinical mastitis in lactating dairy cows in 27 countries by Boehringer Ingelheim since 2008. This combination broadens the spectrum of activity attributed to either agent alone, and synergy between the two agents has been demonstrated against target mastitis pathogens1,2.

Methods for testing the susceptibility of mastitis pathogens to the kanamycin and cefalexin combination, including recommendations for interpretive criteria and quality control ranges for broth microdilution and disk diffusion susceptibility testing, were the subject of prior peer-reviewed publications3,4.

Revised interpretive criteria for the combination for broth microdilution and disk diffusion susceptibility testing were recently approved by the CLSI Veterinary Antimicrobial Susceptibility Testing (VAST) Subcommittee.

“The revised recommendations take into consideration additional susceptibility data collected on recent bovine clinical mastitis field isolates and should be used for testing kanamycin in combination with cephalexin against bovine mastitis pathogens going forward,” shared Dr Laurent Goby, Global Technical Director Ruminants, Boehringer Ingelheim.

Disk diffusion criteria were adjusted accordingly based on the approved broth criteria and resulting error-rate bounding analysis in line with CLSI M23 guidelines5 and were also approved by VAST.

Related posts

BIOMIN Launches Mycofix® Plus 5.Z with ZENzyme® in Asia Pacific


Where does Cargill rank on animal welfare? Among the best, according to this global benchmark


Kenya: Beware of ‘Silent Pneumonia’ in Chicken


Leave a Comment